China forces R&D access in Danaher/GE biopharma deal
Danaher must provide research and development resources for an unfinished project related to the separation and purification of biomolecules as a condition for buying GE’s biopharma business, China’s competition watchdog has decided.
To read more
Subscribe to Global Competition Review
Subscribe and start reading now
Global Competition Review (GCR) is a leading global provider of competition law, regulation and enforcement information, combining data, deep market insight and a user-centric platform to provide our clients with powerful legal solutions.
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10